Equities

IXICO PLC

IXI:LSE

IXICO PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)8.13
  • Today's Change0.00 / 0.00%
  • Shares traded4.83k
  • 1 Year change-57.79%
  • Beta0.7440
Data delayed at least 20 minutes, as of May 03 2024 13:28 BST.
More ▼

Profile data is unavailable for this security.

About the company

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

  • Revenue in GBP (TTM)6.67m
  • Net income in GBP-1.18m
  • Incorporated1995
  • Employees89.00
  • Location
    IXICO PLC4th Fl, Griffin Court, 15 Long LaneLONDON EC1A 9PNUnited KingdomGBR
  • Phone+44 20 3763 7499Fax+44 20 7209 2473
  • Websitehttps://ixico.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Nuformix PLC0.00-436.95k1.43m2.001.43m2.00
ReNeuron Group Plc249.00k-5.07m1.93m34.001.93m34.00
N4 Pharma PLC1.95k-1.28m2.15m5.002.15m5.00
Hellenic Dynamics PLC-100.00bn-100.00bn2.96m25.002.96m25.00
Fusion Antibodies PLC1.58m-2.84m3.19m50.003.19m50.00
TheraCryf PLC838.00k-3.35m3.21m7.003.21m7.00
Oxford Cannabinoid Tchnlgs Hldngs PLC0.00-4.24m3.76m7.003.76m7.00
IXICO PLC6.67m-1.18m3.93m89.003.93m89.00
ValiRx Plc0.00-2.41m4.30m8.004.30m8.00
BSF Enterprise PLC12.94k-1.50m5.17m4.005.17m4.00
Cizzle Biotechnology Holdings PLC0.00-1.72m6.54m67.006.54m67.00
Genflow Biosciences PLC0.00-1.18m7.17m0.007.17m0.00
Data as of May 03 2024. Currency figures normalised to IXICO PLC's reporting currency: UK Pound GBX

Institutional shareholders

50.85%Per cent of shares held by top holders
HolderShares% Held
BGF Investment Management Ltd.as of 04 Dec 20238.92m18.46%
Octopus Investments Ltd.as of 04 Dec 20236.41m13.25%
Canaccord Genuity Wealth Ltd.as of 30 Mar 20214.68m9.69%
Hargreaves Lansdown Asset Management Ltd.as of 01 Feb 20241.76m3.63%
City Asset Management Plcas of 29 Jan 20241.43m2.95%
ICBC Standard Bank Plcas of 01 Feb 2024610.00k1.26%
Pilling & Co. Stockbrokers Ltd.as of 01 Feb 2024267.00k0.55%
HSBC Global Asset Management (UK) Ltd.as of 01 Feb 2024223.00k0.46%
Acadian Asset Management LLCas of 01 Feb 2024151.00k0.31%
BG Fund Management Luxembourg SAas of 01 Feb 2024137.00k0.28%
More ▼
Data from 31 Dec 2023 - 12 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.